06.05.2022 • News

US Court Awards Huntsman Damages Against Praxair

A US court has awarded Huntsman damages in a long-running legal battle against Praxair, now part of Linde. A New Orleans jury has granted the Texas-headquartered chemical manufacturer nearly $94 million, which will exceed $125 million once the Court has applied interest.

Huntsman had accused Praxair of failing to properly maintain its own facility in Geismar, Louisiana, and then repeatedly failing to supply the contracted industrial gas volumes that the chemical company needed to manufacture polyurethane precursor MDI. The long-term supply contracts expired in 2013.

First filed in 2014, the case did not go to trial until this April, because of Covid-19 and other undisclosed factors. The 12-person jury unanimously agreed that Praxair had repeatedly breached its promises to Huntsman, directly causing substantial financial damages.

Peter Huntsman, chairman, president and CEO of Huntsman, said justice was “a very long time coming.” He praised, among others, the company’s polyurethane division and purchasing personnel who he said had “managed the constant operational and commercial upsets occurring when Praxair's poorly-maintained facilities went down from 2004 through 2013.”

In October 2018, Praxair merged with German rival Linde AG into a new company based in the UK and trading as Linde plc.

Author: Elaine Burridge, Freelance Journalist

Photo by Tingey Injury Law Firm on Unsplash
Photo by Tingey Injury Law Firm on Unsplash

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.